UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 001-36644
Calithera Biosciences, Inc.
(Exact name of registrant as specified in its charter)
343 Oyster
Point Blvd., Suite 200
South San Francisco, California 94080
(650) 870-1000
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Common Stock, $0.0001 par value
(Title of each class of securities covered by this Form)
None
(Titles of all
other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the
box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
Rule 12g-4(a)(1) |
|
☒ |
Rule 12g-4(a)(2) |
|
☐ |
Rule 12h-3(b)(1)(i) |
|
☒ |
Rule 12h-3(b)(1)(ii) |
|
☐ |
Rule 15d-6 |
|
☐ |
Rule 15d-22(b) |
|
☐ |
Approximate number of holders of record as of the certification or notice date: 13.
Pursuant to the requirements of the Securities Exchange Act of 1934, Calithera Biosciences, Inc. has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
Date: March 14, 2023 |
|
|
|
By: |
|
/S/ SUSAN M. MOLINEAUX, PH.D. |
|
|
|
|
Name: |
|
Susan M. Molineaux, Ph.D. |
|
|
|
|
Title: |
|
President and Chief Executive Officer |